Array BioPharma analyst commentary at Piper JaffrayPiper Jaffray 'surprised' Array BioPharma shares are trading lower post-results. Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $25 price target for Array BioPharma following the company's Q4 results, telling investors in a research note that he is "surprised" to see shares trading lower today on a "perceived" revenue miss. Tenthoff, who notes that revenues in Q4 were only reimbursement and milestones from partners, says he is a buyer for the Braftovi and Mektovi launch in BRAF-mutant melanoma, which occurred the week of July 2, and projects initial sales of $17.2M in calendar 2018 and $71.5M in calendar 2019.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name.* Own a small position in this name. View the recent decline here as an opportunity to buy more and average in. * $ARRY, Array BioPharma Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.